Skip to main content
    I

    Immunovant Inc (IMVT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $33.28
    -0.90 (-2.63%)

    Market Cap: $7.07B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Immunovant Inc (IMVT) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Immunovant (IMVT) to earn -$2.44 per share in the fiscal year ending Mar 31, 2027. Of 17 analysts, 13 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Mar 31, 2027 were revised up and 3 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 2.12, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 76% of the ratings.

    RatingAnalystsShare
    Strong Buy211.8%
    Buy1164.7%
    Hold423.5%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    17

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss.

    Fiscal year ending Mar 31, 2027
    -$2.44
    EPS consensus
    Fiscal year ending Mar 31, 2028
    -$2.62
    EPS consensus, revenue $39.64M
    Next report
    Feb 4, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Mar 31, 2027-$2.44-$2.55 to -$2.263N/AN/A13
    Mar 31, 2028-$2.62-$3.20 to -$2.385$39.64MN/A13

    Quarterly Estimates

    The EPS consensus falls from -$0.58 for the quarter ending Dec 31, 2026 to -$0.76 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.58-$0.71 to -$0.503
    Mar 31, 2027-$0.76-$0.82 to -$0.6616

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 7 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Mar 31, 202703
    Fiscal year ending Mar 31, 202803
    Quarter ending Dec 31, 202601

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Mar 31, 2027 has improved from -$2.92.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Mar 31, 2027-$2.44-$2.84-$2.84-$2.84-$2.92N/A
    Fiscal year ending Mar 31, 2028-$2.62-$2.75-$2.75-$2.75-$2.50N/A
    Quarter ending Dec 31, 2026-$0.58-$0.67-$0.67-$0.67-$0.74N/A

    Frequently Asked Questions About IMVT

    What is the IMVT stock forecast?

    Consensus analyst estimates put Immunovant's EPS at -$2.44 for the fiscal year ending Mar 31, 2027. The consensus rating from 17 analysts is Buy.

    How do analysts rate IMVT stock?

    Of 17 analysts covering Immunovant, 2 rate it Strong Buy, 11 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from IMVT next year?

    For the fiscal year ending Mar 31, 2027, the consensus EPS estimate is -$2.44, with estimates from -$2.55 to -$2.26 from 3 analysts. For the fiscal year ending Mar 31, 2028, the consensus EPS estimate is -$2.62, with estimates from -$3.20 to -$2.38 from 5 analysts.

    What revenue do analysts expect from Immunovant next year?

    For the fiscal year ending Mar 31, 2028, the consensus revenue estimate is $39.64M.

    How many analysts cover IMVT?

    17 analysts rate Immunovant stock, and 3 analysts estimate its EPS for the fiscal year ending Mar 31, 2027.